Transplant type/clinicohistologic diagnosis and results of adherence assays
Adherence assay . | All patients, first biopsy only; n = 47, clinicohistologic diagnosis3-150 . | Allogeneic transplant patients, all biopsies; n = 40, clinicohistologic diagnosis3-151 . | |||
---|---|---|---|---|---|
Non-GVHD, autologous . | GVHD . | Non-GVHD, allogeneic . | GVHD . | Non-GVHD . | |
+ | 2 | 15 | 23-152 | 24 | 23-152 |
− | 20 | 0 | 8 | 33-153 | 11 |
Adherence assay . | All patients, first biopsy only; n = 47, clinicohistologic diagnosis3-150 . | Allogeneic transplant patients, all biopsies; n = 40, clinicohistologic diagnosis3-151 . | |||
---|---|---|---|---|---|
Non-GVHD, autologous . | GVHD . | Non-GVHD, allogeneic . | GVHD . | Non-GVHD . | |
+ | 2 | 15 | 23-152 | 24 | 23-152 |
− | 20 | 0 | 8 | 33-153 | 11 |
P < .000001, two-tailed (by χ2 test) for all patients, first biopsy only.
P = .00001, two-tailed (by Fisher exact test) for allogeneic transplant patients, all biopsies.
On rebiopsy, both patients met clinicohistologic criteria for acute cutaneous GVHD.
These 3 patients were receiving steroids for therapy of GVHD at time of biopsy (second biopsy), and all had subsequent clinical resolution of skin GVHD.